Cavalry Biosciences

Series-B+
cavalry.bio Biotech & Healthcare San Francisco, United States
Total Funding Undisclosed
Latest Round Undisclosed Series-B+
Last Announced Jun 8, 2026
Investors Undisclosed
Decision Makers 5 Verified

About Cavalry Biosciences

Engineering nature's growth factors into tissue-selective medicines for eye, muscle and nerve repair. Explore our IGF-1 pipeline and regeneration mission.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters San Francisco, United States
Tracked Since Sep 29, 2026

Web & Domain Identity

Official Website cavalry.bio
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Series-B+ announced

    fundraisingfox.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Cavalry Biosciences.

Funding History

1 Round
Series-B+ · Jun 8, 2026

Founders & Leadership

3

Jan van Deursen

Co-founder, Advisor

Work email & phone locked Unlock →

Nathaniel (Ned) David

Co-founder, Chairman

Work email & phone locked Unlock →

Tim Stowe

Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts